Literature DB >> 19505999

Designing 2-phase prevalence studies in the absence of a "gold standard" test.

Agus Salim1, Alan H Welsh.   

Abstract

A population survey for estimating prevalence is challenging when a disease or condition is difficult to diagnose. If clinical diagnosis is expensive, a 2-phase study, in which less expensive but less accurate tests are administered to all study subjects in the first phase (screening phase) and a more accurate but expensive or time-consuming test is administered to only a subset of the subjects in the second phase, is an attractive approach. Published research has discussed ways of maximizing precision of the prevalence estimate from a 2-phase study with a "gold standard" second-phase test. For many psychiatric disorders, even the best diagnostic tests are not of gold standard quality. In this paper, the authors propose a quasi-optimal design for 2-phase prevalence studies without a gold standard test; random-effects latent class analysis facilitates the estimation of prevalence and appropriately addresses the issue of dependent errors among the diagnostic tests. The authors show that the quasi-optimal design is efficient compared with the balanced and random designs when there is strong inter-test dependence caused by additional factors, apart from disease status, and highlight the importance of collecting data on those subjects testing negative in the first phase.

Entities:  

Mesh:

Year:  2009        PMID: 19505999     DOI: 10.1093/aje/kwp122

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  2 in total

1.  Setting criterion thresholds for estimating prevalence: what is being validated?

Authors:  Blase Gambino
Journal:  J Gambl Stud       Date:  2014-09

2.  The Australian Defence Force Mental Health Prevalence and Wellbeing Study: design and methods.

Authors:  Miranda Van Hooff; Alexander C McFarlane; Christopher E Davies; Amelia K Searle; A Kate Fairweather-Schmidt; Alan Verhagen; Helen Benassi; Stephanie E Hodson
Journal:  Eur J Psychotraumatol       Date:  2014-08-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.